Recent News

• 11.18.2025 - Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
• 11.12.2025 - Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
• 11.10.2025 - Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
• 10.22.2025 - Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™
• 10.14.2025 - Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
• 09.08.2025 - Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
• 09.04.2025 - Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
• 08.12.2025 - Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Recent Filings

• 11.12.2025 - 8-K Current report
• 11.12.2025 - EX-99.1 EX-99.1
• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.22.2025 - 8-K Current report
• 10.22.2025 - EX-99.1 EX-99.1
• 09.11.2025 - EX-99.1 EX-99.1
• 09.11.2025 - 8-K Current report
• 08.22.2025 - EFFECT Notice of Effectiveness
• 08.20.2025 - CORRESP Correspondence
• 08.15.2025 - UPLOAD SEC-generated letter